Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Is Confident In Prexige’s Prospects Despite Arcoxia AC Debacle

Executive Summary

Novartis is confident its COX-2 inhibitor Prexige does not raise the same safety concerns cited by an FDA advisory committee in recommending against approval of Merck's COX-2 agent Arcoxia

You may also be interested in...

Arcoxia Needs Further Study In 1,000s Of Patients, Or Discontinuation – Cmte

Merck's COX-2 inhibitor Arcoxia requires significant additional clinical safety and efficacy evaluation prior to approval, members of FDA's Arthritis Drugs Advisory Committee said in recommending against approval of the Vioxx follow-on for treatment of osteoarthritis

Door Open For Zelnorm Return Despite Marketing “Suspension,” Novartis Says

Novartis is emphasizing that the removal of Zelnorm from the market is a suspension rather than a withdrawal

Prexige Still Postponed: Novartis To Resubmit COX-2 Inhibitor In U.S. In 2007

Novartis plans to resubmit Prexige (lumiracoxib) in the U.S. in the first half of 2007; approval of the oral COX-2 inhibitor in the European Union and Canada for treatment of osteoarthritis symptoms was announced Nov. 7

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts